Groningen, the Netherlands, Aug 12, 2013 – Biotechnology company Mucosis B.V. today announced the publication in the peer-reviewed journal PLOS ONE of preclinical data showing that its innovative SynGEM® is safe and protective in animal models. According to the report, SynGEM®, a vaccine based on the Mimopath® vaccine technology allows presentation of a stable prefusion-like… Continue reading Mucosis announces publication of data demonstrating safety and protection by mucosally administered Mimopath®-based prefusion-like F RSV vaccines
Category: news
Prosensa Awarded EUR 6 million EU FP7 Research Grant
LEIDEN, The Netherlands – August 1, 2013 – Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that it has been awarded a prestigious Framework Programme 7 (FP7) research grant from the European Union to support the ongoing clinical study of the… Continue reading Prosensa Awarded EUR 6 million EU FP7 Research Grant
Kiadis Pharma to receive GMP manufacturing license and GMP certificate
Amsterdam, The Netherlands, July 23, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that its Quality Control (QC) laboratory and the associated Quality system has been inspected for good-manufacturing-practice (GMP) by the Dutch Health Care Inspectorate (IGZ) and has fully met the EU GMP standards. As… Continue reading Kiadis Pharma to receive GMP manufacturing license and GMP certificate
Prosensa Holding N.V. announces closing of Initial Public Offering
Leiden, the Netherlands—July 8, 2013—Prosensa Holding N.V. (“Prosensa”) announced today the closing of its previously announced initial public offering of 6,900,000 of its ordinary shares at a price of $13.00 per share (including an additional 900,000 ordinary shares pursuant to the exercise of the over-allotment option by the underwriters). The ordinary shares began trading on… Continue reading Prosensa Holding N.V. announces closing of Initial Public Offering
Prosensa Holding B.V. prices Initial Public Offering
Leiden, the Netherlands—June 27, 2013—Prosensa Holding B.V. (“Prosensa”) announced today the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of $13.00 per share, before underwriting discounts. Prosensa has also granted the underwriters a 30-day option to purchase up to an additional 900,000 ordinary shares to… Continue reading Prosensa Holding B.V. prices Initial Public Offering
